摘要
目的 :观察比索洛尔 (bisoprolol)长期治疗充血性心衰患者后 ,血浆内降钙素基因相关肽 (CGRP) ,内皮素 (ET 1)浓度变化和对心脏功能的影响 .方法 :将符合本试验纳入标准的 68例心衰患者分成试验组 (n =3 0 )和对照组 (n =3 8) ,患者均口服地高辛、ACEI制剂、血管扩张剂 (非钙离子拮抗剂 )和利尿剂等基本抗心衰药物 ,在此基础上试验组加服比索洛尔 .测定患者试验初始时和服药 7mo后血浆CGRP和ET 1的浓度及其心脏射血分数 (ejectionfraction ,EF % ) .结果 :随访 7mo后 ,试验组患者血浆中CGRP和ET 1浓度较试验初显著性降低 (P <0 .0 1) ,与对照组比较均明显降低 (P <0 .0 1) ;复查心脏B超EF %平均值 :对照组 (3 4 .0± 3 .5 ) %和试验组 (42 .0± 3 .2 ) % ,与试验初比较两组均有显著的改善 ,而 7mo后试验组较对照组有显著的升高 (P <0 .0 1) .结论 :在基本心衰治疗用药的基础上加用比索洛尔治疗 7mo后 ,可以降低血浆CGRP和ET 1浓度 ,减轻有害因子的毒副作用 ,使心肌重塑过程得到缓解 .加用比索洛尔治疗
AIM: To study the effects of bisoprolol on plasma calcitonin gene related peptide (CGRP), endothelin (ET) 1 levels and heart functions in patients with chronic heart failure.METHODS: Sixty eight patients with chronic heart failure were divided into two groups: the bisoprolol group and the control group. Blood samples were drawn from median cubital veins of all these patients at the beginning of the study and follow up after the 7 month. The plasma concentration of ET 1 and CGRP were detected by radioimmunoassay, and the left ventricular ejection fraction (EF%) were recorded to evaluate the effects of bisoprolol.RESULTS: At the end of 7 month follow up, the plasma concentrations of ET 1 and CGRP in bisoprolol group decreased significantly compared with those at the beginning of the study ( P < 0.01) and it was also true compared with those of the control group ( P <0.01).The values of EF% were higher in both groups after 7 month follow up, and the values of EF% was significantly higher in the bisoprolol group than those in the control group (all P <0.01). CONCLUSION: Bisoprolol added to other routine drugs can decrease the levels of the plasma CGRP and ET 1 and improve the heart functions of patients with heart failure.
出处
《第四军医大学学报》
北大核心
2003年第7期658-660,共3页
Journal of the Fourth Military Medical University
